EGFR and non-small cell lung carcinoma: Starting with the BeTa lung phase 3 study, the combination of bevacizumab and erlotinib was tested in patients of NSCLC without EGFR mutation stratification, and subgroups analyses showed patients with EGFR-positive NSCLC responded better to the combination13.